Prohibitin 1 (PHB1) is best known as a mitochondrial chaperone, and its role in cancer is conflicting. Mice lacking methionine adenosyltransferase a1 (MATa1) have lower PHB1 expression, and we reported that c-MYC interacts directly with both proteins. Furthermore, c-MYC and MATa1 exert opposing effects on liver cancer growth, prompting us to examine the interplay between PHB1, MATa1, and c-MYC and PHB1's role in liver tumorigenesis. We found that PHB1 is highly expressed in normal hepatocytes and bile duct epithelial cells and down-regulated in most human hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). In HCC and CCA cells, PHB1 expression correlates inversely with growth. PHB1 and MAT1A positively regulate each other's expression, whereas PHB1 negatively regulates the expression of c-MYC, MAFG, and c-MAF. Both PHB1 and MATa1 heterodimerize with MAX, bind to the E-box element, and repress E-box promoter activity. PHB1 promoter contains a repressive E-box element and is occupied mainly by MAX, MNT, and MATa1 in nonmalignant cholangiocytes and noncancerous tissues that switched to c-MYC, c-MAF, and MAFG in cancer cells and human HCC/CCA. All 8-month-old liver-specific Phb1 knockout mice developed HCC, and one developed CCA. Five-month-old Phb1 heterozygotes, but not Phb1 flox mice, developed aberrant bile duct proliferation; and one developed CCA 3.5 months after left and median bile duct ligation. Phb1 heterozygotes had a more profound fall in the expression of glutathione synthetic enzymes and higher hepatic oxidative stress following left and median bile duct ligation. Conclusion: We have identified that PHB1, down-regulated in most human HCC and CCA, heterodimerizes with MAX to repress the E-box and positively regulates MAT1A while suppressing c-MYC, MAFG, and c-MAF expression; in mice, reduced PHB1 expression predisposes to the development of cholestasis-induced CCA. (HEPATOLOGY 2017;65:1249-1266. P rohibitin 1 (PHB1) belongs to an evolutionarily conserved and ubiquitously expressed family of proteins with a myriad of functions in different cellular compartments.
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Prohibitin 1 (PHB1) is best known as a mitochondrial chaperone, and its role in cancer is conflicting. Mice lacking methionine adenosyltransferase a1 (MATa1) have lower PHB1 expression, and we reported that c-MYC interacts directly with both proteins. Furthermore, c-MYC and MATa1 exert opposing effects on liver cancer growth, prompting us to examine the interplay between PHB1, MATa1, and c-MYC and PHB1's role in liver tumorigenesis. We found that PHB1 is highly expressed in normal hepatocytes and bile duct epithelial cells and down-regulated in most human hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). In HCC and CCA cells, PHB1 expression correlates inversely with growth. PHB1 and MAT1A positively regulate each other's expression, whereas PHB1 negatively regulates the expression of c-MYC, MAFG, and c-MAF. Both PHB1 and MATa1 heterodimerize with MAX, bind to the E-box element, and repress E-box promoter activity. PHB1 promoter contains a repressive E-box element and is occupied mainly by MAX, MNT, and MATa1 in nonmalignant cholangiocytes and noncancerous tissues that switched to c-MYC, c-MAF, and MAFG in cancer cells and human HCC/CCA. All 8-month-old liver-specific Phb1 knockout mice developed HCC, and one developed CCA. Five-month-old Phb1 heterozygotes, but not Phb1 flox mice, developed aberrant bile duct proliferation; and one developed CCA 3.5 months after left and median bile duct ligation. Phb1 heterozygotes had a more profound fall in the expression of glutathione synthetic enzymes and higher hepatic oxidative stress following left and median bile duct ligation. Conclusion: We have identified that PHB1, down-regulated in most human HCC and CCA, heterodimerizes with MAX to repress the E-box and positively regulates MAT1A while suppressing c-MYC, MAFG, and c-MAF expression; in mice, reduced PHB1 expression predisposes to the development of cholestasis-induced CCA. (HEPATOLOGY 2017;65:1249-1266). P rohibitin 1 (PHB1) belongs to an evolutionarily conserved and ubiquitously expressed family of proteins with a myriad of functions in different cellular compartments. (1, 2) PHB1 is best known as a mitochondrial chaperone that is essential for mitochondrial function and biogenesis. (2) PHB1 is also present in the nucleus, where it serves as a transcription cofactor and interacts with many proteins including retinoblastoma and p53 to repress or activate the transcriptional activities of E2F (3, 4) or p53, (5) respectively. Recently we reported that hepatic PHB1 expression is down-regulated at the mRNA and protein levels in chronic cholestatic injury in experimental murine models and in humans. (6, 7) We found that PHB1 interacts directly with nuclear erythroid 2 p45-related factor 2 (NRF2) and serves as a coactivator of the antioxidant response element (ARE) to positively regulate AREdependent genes such as glutamate-cysteine ligase. (6) In contrast, c-MYC serves as a corepressor and inhibits NRF2-ARE activity. (6) We also found crosstalk between c-MYC and methionine adenosyltransferase a1 (MATa1, encoded by MAT1A) in cholestatic liver injury and cholangiocarcinoma (CCA), where the two exert reciprocal regulation against each other at the transcriptional level. (8) MATa1 expression falls in chronic cholestatic liver injury, while c-MYC expression is induced, (8) and we showed the induction of c-MYC is a key driver in cholestasis-associated CCA. (9) Consistently overexpressing MAT1A inhibited CCA growth in vivo as effectively as silencing c-MYC, while silencing MAT1A promoted CCA growth, which was comparable to overexpressing c-MYC. (8) Interestingly, mice lacking MATa1 have reduced PHB1 expression, (10) and both Mat1a and liver-specific Phb1 knockout (KO) mice develop hepatocellular carcinoma (HCC) spontaneously. (11, 12) While the suppressive role of MATa1 in liver cancer tumorigenesis is well characterized, (13, 14) the role of PHB1 is controversial and unclear. The goals of the current work were to examine whether there is interplay between PHB1, MATa1, and c-MYC and to define the role of PHB1 in the tumorigenesis of HCC and CCA, the two most common primary cancers of the liver.
Materials and Methods

MATERIALS AND REAGENTS
a-
32 P deoxycytidine triphosphate (6,000 Ci/mmol) was purchased from PerkinElmer (Boston, MA). Antibodies used for western blotting, chromatin immunoprecipitation (ChIP), sequential ChIP (SeqChIP), and immunohistochemistry (IHC) of PHB1, MATa1, c-MYC, MAFG, c-MAF, b-actin, and immunoglobulin G (IgG) were purchased from Abcam (Cambridge, MA). Lipofectamine 2000 and RNAi-Max were purchased from ThermoFisher (Carlsbad, CA). Small interfering RNAs to PHB1 (catalog no. 4392422), c-MYC
, and MAT1A (5 0 -GCACAACGAAGACAUCACGtt-3 0 ) were purchased from ThermoFisher. Bile acids and interleukin-6 (IL-6) were from Sigma (St. Louis, MO).
SOURCE OF NORMAL LIVER AND HUMAN HCC AND CCA WITH ADJACENT NONTUMOROUS SPECIMENS
Specimens were obtained from three hospitals, two in the United States (Cedars-Sinai Medical Center, Los Angeles, CA, and the Mayo Clinic, Rochester, MN) and one in China (Xiangya Hospital Central South University, Changsha, Hunan Province, China). From China, 27 pairs of fresh-frozen HCC and three pairs of fresh-frozen CCA and adjacent benign tissue samples were obtained from patients undergoing surgical liver resection. All fresh-frozen samples were collected from 2013 to 2016, stored in the biobank, and kept in a liquid nitrogen tank for long-term storage. In addition, five other paraffin-embedded normal liver tissues and five CCA specimens were used for IHC. All samples were verified by three pathologists at the Department of Pathology, Central South University. Approval for the use of human samples was obtained from the institutional review board of the Central South University, Xiangya Hospital Authority. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the Medical Ethical Committee of Xiangya Hospital Central South University.
From Cedars-Sinai Medical Center, six pairs of archived fresh-frozen HCC, seven pairs of CCA, and adjacent benign tissue samples were obtained from patients undergoing surgical liver resection. From the Mayo Clinic seven pairs of CCA and adjacent benign tissue samples were accessed and provided as deidentified samples. Protocols were approved by the institutional review boards of Cedars-Sinai Medical Center and the Mayo Clinic. Both tumor and normal tissues were evaluated histologically to confirm the presence or absence of neoplasm. These samples were used to measure PHB1 mRNA levels (see below).
ANIMAL EXPERIMENTS
The mice were housed in a vented rack system in standard vented microisolator cages containing wood chip bedding and fed a standard mouse chow consisting of 13.4% fat, 29.8% protein, and 57.8% carbohydrates (Standard Diet # 5001, LabDiet, St. Louis, MO). The mice were subjected to a standard 12-hour light/dark cycle. None of the mice were fasted and treatments and surgical procedures described below were done during the light cycle. Both Mat1a KO and liver-specific Phb1 KO mice in C57/B6 background have been described. (11, 12) Five-month-old male liverspecific Phb1 heterozygotes and Phb1 flox controls (n 5 8/group) were subjected to left and median bile duct ligation (LMBDL) as we described (9) and observed for up to 3.5 months afterward. Parts of the liver tissues were used for RNA and protein analysis, and the rest were fixed in 4% formalin for histology and IHC. The murine cholestasis-associated CCA model has been described. (9) Briefly, 7-week old male Balb/c mice were given 2 weekly intraperitoneal injections of diethylnitrosamine (DEN, 100 mg/kg); 2 weeks later, some mice also received LMBDL and then, 1 week later, were fed DEN (25 mg/kg in corn oil), weekly by oral gavage (DEN1LMBDL1DEN [DLD] ). CCA developed at week 28 in the DLD group but not in groups that received only DEN or LMBDL. (9) The effect of c-MYC was evaluated using short hairpin RNA as described. (9) CCA specimens from our previous study (9) were used for measurement of mRNA levels. All treatment controls were littermates. All procedure protocols, use, and the care of the animals were reviewed and approved by the Institutional Animal Care and Use Committee at Cedars-Sinai Medical Center.
CELL LINES AND TREATMENTS TO VARY GENE EXPRESSION
Human CCA KMCH and Huh28 and HCC HepG2 and Hep3B cell lines were cultured in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 0.1 mg/mL streptomycin, and 2 mmol/L L-glutamine. H69 cells and SV40 transformed normal human biliary epithelial cells were cultured as described. (15) To examine the interplay between PHB1 or MATa1 and c-MYC/MAFG/c-MAF, 1 3 ) were grown in 0.7% soft agar on a 0.5% base soft agar layer in a six-well plate for 2 weeks in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum and G418. Plates with only soft agar layers and no cells served as negative controls. Colonies formed at the end of 2 weeks were stained with 0.005% crystal violet for 1 hour and washed thoroughly with water, and images were acquired using an Evos Advanced Microscopy Group transmitted light microscope coupled with Evos xl software (AMG, Bothell, WA).
PROMOTER CONSTRUCTS AND LUCIFERASE ASSAY
Human PHB1 promoter (1.2 kb) was generated using the upstream primer AGGTAAAAACTA-GAATGAGAGCTGAGC (bp -1150 to -1124) and the reverse downstream PCR primer ACACCTGCTTCCACTCTGACCTC (bp 128 to 150, NM-002634) from a human genomic DNA (BioLINE, Taunton, MA). The fragment was cloned into a pEZX-PG02.1 vector between EcoRI sites from GeneCopoeia. The wild-type E-box-luc and mutant E-box-luc where the core motif of E-box CACGTG was changed to CTCGTC have been described. (8) The promoter constructs and pGL4.13/SV40 (1 lg) were cotransfected into KMCH, Huh28, HepG2, and Hep3B cells with Lipofectamine 2000 following the manufacturer's instructions. Luciferase assays were performed 24 hours later using the Pierce Gaussia Luciferase Flash Assay Kit (ThermoFisher) and the Dual Luciferase Reporter Assay System (Promega, Madison, WI) as directed by the manufacturer's suggested protocol.
HISTOLOGY AND IMMUNOHISTOCHEMISTRY
Formalin-fixed liver and CCA tissues embedded in paraffin were cut and stained with hematoxylin and eosin for routine histology. IHC staining of PHB1, MATa1, c-MYC, MAFG, c-MAF, and IgG was performed with a kit from Dako (Carpinteria, CA) or Abcam according to the manufacturer's method. Control with normal mouse IgG showed no staining (not shown). The OxyIHC kit (Millipore, Billerica, MA) was used to determine oxidative stress in liver tissues following the manufacturer's protocol.
RNA ISOLATION AND GENE EXPRESSION ANALYSIS
Total RNA was isolated using the Quick-RNA miniPrep kit (Zymo Research, Irvine, CA) from cell lines and murine and human liver tissues, HCC, CCA, and adjacent nontumorous tissues. Gene expression was assessed using real-time PCR. Total RNA was subjected to reverse transcription using Moloney murine leukemia virus reverse transcriptase (Lucigen, Middleton, WI). TaqMan probes for human and murine PHB1, MAT1A, c-MYC, MAFG, c-MAF, glutamate-cysteine ligase catalytic and modifier subunits (Gclc and Gclm), and the Universal PCR Master Mix were purchased from Bio-Rad (Hercules, CA). Hypoxanthine phosphoribosyltransferase 1 or glyceraldehyde 3-phosphate dehydrogenase (for human CCA) was used as a housekeeping gene. The thermal profile consisted of an initial denaturation at 958C for 3 minutes, followed by 40 cycles at 958C for 3 seconds and at 608C for 30 seconds. The cycle threshold (Ct value) of the target genes was normalized to that of the housekeeping gene to obtain the delta Ct (DCt). The DCt was used to find the relative expression of target genes according to the following formula: relative expression 5 2 -DDCt , where DDCt 5 DCt of target genes in experimental condition -DCt of target gene under control condition.
ChIP AND Seq-ChIP ASSAY
ChIP and Seq-ChIP were done to examine changes in protein binding to the E-box region of the human PHB1 promoter in an endogenous chromatin configuration using the manufacturer's suggested protocol from the Pierce agarose ChIP kit (ThermoFisher). Briefly, DNA immunoprecipitated by MAX antibody was processed for a second round of immunoprecipitation using anti-MATa1, anti-c-MYC, anti-MAFG, anti-c-MAF, anti-PHB1, or anti-MNT antibodies. The purified DNA was detected by PCR analysis. PCR of the human PHB1 promoter region containing the E-box used forward primer
to -365) and reverse primer 5 0 -TTGGTGATCAACGCGAGGATGTTG-3 0 (-208 to -185 relative to the transcriptional start site) (GenBank accession no. NM-002624). All PCR products were run on 2% agarose gels. The PCR conditions consisted of an initial denaturation at 948C for 3 minutes, followed by 25 cycles at 948C for 30 seconds and annealing and extension at 678C for 90 seconds using the Advantage GC 2 PCR kit (Clontech, Mountain View, CA), in accordance with the manufacturer's suggested protocol.
WESTERN BLOT AND COIMMUNOPRECIPITATION ANALYSIS
Total protein extracts from cells expressing varying amounts of PHB1, MATa1, C-MYC, MAFG, and c-MAF were subjected to western blot analysis as described. (14) Equal amounts of total protein extracts (15 lg/well) were resolved on 12.5% sodium dodecyl sulfate-polyacrylamide gels. Membranes were probed with antibodies to PHB1, MATa1, c-MYC, MAFG, and c-MAF. To ensure equal loading, membranes were stripped and reprobed with anti-actin antibodies. Blots were developed by enhanced chemiluminescence (Millipore). For coimmunoprecipitation, proteins were immunoprecipitated by anti-PHB1 antibody and then subjected to western blotting with antibody to MATa1, c-MYC, MAFG, c-MAF, or glyceraldehyde 3-phosphate dehydrogenase. (12) were subjected to immunoprecipitation using anti-PHB1 or nonspecific IgG, followed by western blotting for MAFG, MATa1, c-MYC, c-MAF, PHB1, and glyceraldehyde 3-phosphate dehydrogenase (as negative control). (B) In vitro pulldown assay using immobilized recombinant PHB1 or MATa1 demonstrates direct interaction between PHB1 and MATa1. (C) In vitro pull-down assay using immobilized recombinant PHB1 or MAFG demonstrates direct interaction between PHB1 and MAFG. Results represent a total of at least three independent experiments. Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IP, immunoprecipitation; r, recombinant.
FIG. 2.
PHB1 suppresses growth in HCC and CCA cells and is down-regulated in human HCC and CCA. Effect of varying PHB1 expression on growth of two HCC (HepG2 and Hep3B) and two CCA (KMCH and Huh28) cell lines was assessed using BrdU, as described in Materials and Methods. (A) Overexpression of PHB1 suppressed BrdU incorporation, similar to overexpression of MAT1A or knocking down c-MAF, MAFG, or c-MYC. In contrast, overexpression of c-MAF, MAFG, and c-MYC all increased BrdU incorporation, similar to knocking down MAT1A or PHB1. *P < 0.05 versus respective controls. (B) IHC analysis of PHB1, MATa1, c-MYC, MAFG, and c-MAF in paraffin-embedded specimens from human HCC and CCA. In normal liver, PHB1 is highly expressed in hepatocytes and bile duct epithelial cells but is down-regulated in CCA. PHB1 and MATa1 are highly expressed in nontumorous livers and down-regulated in HCC. In contrast, c-MYC, MAFG, and c-MAF have low expression in nontumorous livers and are up-regulated in HCC. Arrows point to the small bile duct (insets at the bottom right of the IHC image). Original magnification 3200. (C) PHB1 mRNA levels in four independent HCC microarrays from GEO database compared to adjacent nontumor tissue. (D) PHB1 mRNA levels from the only GEO database that contains information on CCA (GSE15765) show lower expression in CCA compared to HCC. The database normalized PHB1 expression by the robust multiarray average method. (31) Abbreviations: GSE, gene set evaluation; NT, nontumor; OV, overexpression; RMA, robust multiarray average; si, small interfering.
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DIRECT PROTEIN-PROTEIN INTERACTION
Recombinant human PHB1, MATa1, and MAFG proteins were from Prospec (East Brunswick, NJ). MATa1, MAFG, or PHB1 protein (2 lg) was immobilized to agarose beads by their respective antibody. After washing, beads were mixed with 1 lg PHB1, MATa1, or MAFG protein and rotated for 4 hours at 48C. Beads were then washed six times and boiled in sodium dodecyl sulfate sample buffer, and proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and subjected to western blotting.
ELECTROPHORETIC MOBILITY SHIFT ASSAY WITH RECOMBINANT PROTEINS
Binding of recombinant human PHB1, MATa1, MAX, and c-MYC (200 ng) alone or in different combinations to the E-box of the human PHB1 promoter (bp -260 to -245 relative to the transcriptional start site) was examined with an electrophoretic mobility shift assay as we described. 
STATISTICAL ANALYSIS
Data are expressed as mean 6 standard error of the mean. Statistical analysis was performed using analysis of variance and Fisher's test. For mRNA and protein levels, ratios of genes and proteins to respective housekeeping densitometric values were compared. Significance was defined by P < 0.05.
Results
PHB1 INTERACTS WITH MATa1, MAFG, c-MAF, AND c-MYC
We have shown that PHB1 directly interacts with c-MYC, (6) which in turn directly interacts with MATa1, MAFG, and c-MAF. (8) To see if PHB1
interacts with MATa1, MAFG, and c-MAF in the normal mouse liver, we used coimmunoprecipitation with anti-PHB1 antibody followed by western blotting. This revealed that MATa1, MAFG, c-MAF, and c-MYC to be interacting proteins with PHB1 (Fig. 1A) . To examine whether the interactions are direct, we used recombinant proteins immobilized to beads and found that PHB1 can directly interact with MATa1 (Fig. 1B) and MAFG (Fig. 1C) .
PHB1 SUPPRESSES GROWTH IN HCC AND CCA CELLS AND IS DOWN-REGULATED IN HUMAN HCC AND CCA
We showed that MATa1 is a tumor suppressor in HCC and CCA cells (8, 14) and c-MYC, MAFG, and c-MAF all behave as oncoproteins in CCA cells. (8) PHB1 is similar to MATa1 in both CCA and HCC cells as overexpression of either protein suppressed growth, while knockdown increased growth ( Fig. 2A) . In contrast, c-MYC, MAFG, and c-MAF all increased growth when overexpressed in both HCC and CCA cells (Fig. 2A) . PHB1 is highly expressed in normal hepatocytes and bile duct epithelial cells, and its expression is markedly reduced in human HCC and CCA specimens, similar to MATa1 (Fig. 2B) . We showed that c-MYC, MAFG, and c-MAF are induced in human CCA (8) ; and here we found they are induced in HCC as well (Fig. 2B) . In four independent HCC microarray data sets from the Gene Expression Omnibus (GEO) database, PHB1 mRNA levels are reduced in HCC compared to adjacent nontumorous tissue in the majority (Fig. 2C) . We found only one available CCA microarray data set from the GEO database (GSE15765) and that PHB1 mRNA levels are lower in CCA compared to HCC (Fig. 2D) . We verified these changes using our own available specimens. Consistent with these results, of the paired HCC and CCA samples (tumor and adjacent nontumorous tissue from the same patients) available, 22 of 33 HCCs and 14 of 17 CCAs showed lower PHB1 mRNA levels in the tumors to 44% 6 6% and 30% 6 5% of adjacent nontumorous tissues, respectively. 
FIG. 4.
PHB1 and MATa1 heterodimerize with MAX, bind to the E-box, and repress E-box-driven promoter activity. (A) Electrophoretic mobility shift assay analysis of a multimerized human PHB1 E-box element (X3) using recombinant PHB1, MATa1, c-MYC, and MAX proteins in different combinations. PHB1 cannot bind to E-box alone or with c-MYC but can bind to E-box in the presence of MAX, similar to MATa1. (B) Promoter activity of a consensus E-box-driven luciferase reporter construct and its mutant after overexpression or knockdown of PHB1 in two HCC and two CCA cell lines. *P < 0.05 versus respective controls. Results represent a total of at least three independent experiments done in duplicate. Abbreviations: EV, empty vector; mut, mutant; NS, nonspecific; OV, overexpression; SC, scramble; si, small interfering.
but negatively regulates c-MYC, MAFG, and c-MAF. Overexpressing PHB1 raised MAT1A mRNA and protein levels but lowered the mRNA and protein levels of c-MYC/MAFG/c-MAF in both HCC and CCA cells (Fig. 3A) . The opposite was true of PHB1 knockdown (Fig. 3B) . In turn, PHB1 expression is regulated positively by MAT1A but negatively by c-MYC, MAFG, and c-MAF (Fig. 3C ).
PHB1 AND MATa1 HETERODIMERIZE WITH MAX, BIND TO THE E-BOX, AND REPRESS E-BOX-DRIVEN PROMOTER ACTIVITY
We showed that MATa1, c-MYC, MAFG, and c-MAF all interact at the E-box, with MATa1 repressing the E-box and the other three activating the E-box. (8) Here, we found that both PHB1 and MATa1 only need MAX in order to bind to the E-box (Fig. 4A) . Figure 4B shows that PHB1 represses E-box-driven promoter activity as overexpression lowered, while knockdown of PHB1 raised, E-box-driven promoter activity. This was true in both HCC and CCA cell lines and did not occur if the E-box was mutated (Fig. 4B) .
OCCUPANCY OF THE PHB1 PROMOTER E-BOX AND ITS REGULATION BY MATA1, c-MYC, MAFG, AND c-MAF
The PHB1 promoter region contains an E-box close to the transcription start site (Fig. 5A) . In nonmalignant cholangiocytes H69, MNT, MATa1, and PHB1 are the predominant proteins that co-occupy this region. However, in malignant HCC and CCA cells, this is switched to c-MYC, c-MAF, and MAFG (Fig. 5A) . The same is true in human HCC and CCA, where cooccupancy of the human PHB1 promoter E-box region is switched from MNT, MATa1, and PHB1 in noncancerous tissues to c-MYC, c-MAF, and MAFG in HCC or CCA (Fig. 5B) . Regulation of the human PHB1 promoter by these proteins is confirmed as overexpressing MAT1A increased PHB1 promoter activity, while overexpressing c-MYC, MAFG, or c-MAF lowered PHB1 promoter activity. These effects were eliminated if the E-box site was mutated (Fig. 5C ).
LIVER-SPECIFIC Phb1 KO MICE DEVELOP HCC AND CCA, AND HETEROZYGOTES ARE SENSITIZED TO DEVELOP CCA FOLLOWING LMBDL
Consistent with results obtained from the HCC and CCA cells, liver-specific Phb1 KO livers have elevated c-Myc, c-Maf, and Mafg but reduced Maf1a mRNA levels and protein expression (Fig. 6A,B) . As we reported, (12) all 8-month-old KO mice developed HCC but most (six of eight) also exhibited aberrant bile duct proliferation and one developed CCA (Fig.  6C-E) . Five-month-old liver-specific Phb1 heterozygotes do not have any overt phenotype and have normal serum alanine aminotransferase levels (data not shown). However, they are sensitized to develop aberrant bile duct proliferation, and one developed frank CCA with pancreas and lung metastasis only 3.5 months after LMBDL (Fig. 7A-C) . This did not occur in any of the Phb1 flox mice subjected to LMBDL. LMBDL resulted in lowering of Mat1a and Phb1 but higher c-Myc, c-Maf, and Mafg mRNA levels in both flox controls and heterozygotes, with the heterozygotes exhibiting a greater degree of change compared to flox controls (Fig. 7D) . Changes in PHB1 protein levels were verified using western blotting (Fig.  7E ). Because PHB1 is also important as a coactivator of NRF2 for ARE-dependent genes, (6) we examined expression of Gclc and Gclm. Consistent with our previous findings, (6) Phb1 heterozygotes have lower baseline Gclc and Gclm mRNA levels that fell further after LMBDL (Supporting Fig. S1 ). This translated to higher levels of oxidative stress in the liver tissue, particularly around the periportal region, in both hepatocytes and biliary epithelial cells (Supporting Fig. S2 ).
PHB1 EXPRESSION CORRELATES INVERSELY WITH GROWTH IN THE MURINE CCA MODEL
We examined the murine CCA model we described (9) where c-MYC is a key driver for tumor growth. CCA development required both DEN and LMBDL (DLD) in wild-type mice in this model. (9) We found that Phb1 mRNA levels were 51% lower in the DLD group compared to the DEN or LMBDL only groups (Supporting Fig. S3A ). Reducing the cMyc mRNA level with short hairpin RNA suppressed tumor growth (9) and consistently raised Phb1 mRNA levels more than 100% (Supporting Fig. S3B ).
PHB1 IS A TUMOR SUPPRESSOR IN SAMe-D CELLS
SAMe-D cells are HCC cells derived from the Mat1a KO mouse. (16) SAMe-D cells express much lower PHB1 compared to normal mouse hepatocytes (Fig. 8A) . SAMe-D cells overexpressing PHB1 have 
FIG. 7.
Liver-specific Phb1 heterozygotes are sensitized to develop LMBDL-induced CCA. Five-month-old liver-specific Phb1 heterozygotes and flox controls (n 5 8/group) were subjected to LMBDL as described in Materials and Methods and followed for 3.5 months. lower c-MYC, c-MAF, and MAFG protein levels (Fig. 8B) . SAMe-D cells exhibit anchorageindependent growth, which is markedly inhibited when PHB1 is stably expressed (Fig. 8C) .
ROLE OF BILE ACIDS AND IL-6 IN SUPPRESSING PHB1 EXPRESSION DURING CHOLESTASIS
We examined the effects of CA, CDCA, and GDCA on PHB1 expression in H69 cells compared to lithocholic acid as a positive control. CA and CDCA had no effects on PHB1 expression at 50 or 100 lM. GDCA at 100 lM lowered MAT1A and PHB1 mRNA levels by 20% and 15%, respectively, while raising MAFG, c-MYC, and c-MAF by 30%, 51%, and 71%, respectively (Supporting Fig. S4A ). No effect occurred at 50 lM GDCA. We also examined IL-6 (10 ng/mL for 4 hours) and found that it lowered MAT1A and PHB1 mRNA levels by 21% and 26% while raising c-MYC, MAFG, and c-MAF mRNA levels by 39%, 46%, and 53%, respectively (Supporting Fig. S4B ).
Discussion
PHB1 is best known for its role in the mitochondria, but there is increasing evidence that it is involved in multiple other pathways related to its subcellular localization that include the nucleus and the lipid rafts of the plasma membrane. (17) Within the mitochondria two homologous PHB proteins, PHB1 and PHB2, form a large multimeric complex in the inner mitochondrial membrane, where it exerts a chaperone-like function to stabilize newly synthesized mitochondrial proteins (2) and maintains the organization and stability of mitochondrial nucleoids. (18) Within the nucleus PHB1 interacts with multiple proteins to modulate the transcriptional activity of transcription factors such as p53 and E2F. (17) We recently added NRF2 and c-MYC to the list of transcription factors that interact with PHB1. (6) We found that PHB1 and c-MYC function to enhance or repress NRF2 binding to the ARE and ARE-dependent gene expression, respectively. (6) Importantly PHB1 expression falls during chronic cholestatic liver injury in experimental mouse models as well as in humans with primary biliary cirrhosis, biliary atresia, and Alagille syndrome. (6, 7) In contrast, c-MYC expression is rapidly induced following cholestatic liver injury and these changes contributed significantly to the down-regulation of two ARE-dependent genes, GCLC and GCLM, and to lower glutathione (GSH) levels. (6) In addition to positively regulating NRF2-ARE activity, PHB1 interacts with histone deacetylase 4 and keeps it in the cytosol. During cholestasis the fall in PHB1 expression allows histone deacetylase 4 to translocate to the nucleus to alter gene expression through epigenetics. (7) Thus, the fall in PHB1 expression during cholestasis can negatively affect mitochondrial function and expression of GSH synthetic enzymes and lead to histone deacetylase 4-mediated epigenetic changes. Whether decreased PHB1 expression participates in cholestasisassociated CCA development has never been examined.
The role of PHB1 in cancer is mixed and controversial. PHB1 was originally cloned from regenerating livers, where its expression was found to be nearly absent shortly after two-thirds partial hepatectomy and it was thought to be a tumor suppressor (hence its name). (19) However, the tumor suppressive role of PHB1 has been controversial as PHB1 expression is higher in many cancers, (2) which was thought to be related to the fact that its promoter region contains many c-MYC binding sites and c-MYC is often induced in cancer. (20) Nevertheless, a clear tumor suppressive role of PHB1 has been demonstrated in breast, gastric, and prostate cancers. (17, 21) Overexpressing PHB1 in intestinal epithelial cells was also found to attenuate colitisassociated colon cancer tumorigenesis in mice. (22) Importantly, PHB1 expression falls in intestinal inflammation, including patients with inflammatory bowel disease, (22) making this observation very relevant for the increased susceptibility of these patients to colon cancer.
We reported that liver-specific Phb1 KO mice developed multifocal HCC. (12) Although this may have occurred in part due to the regenerative response to severe liver injury, we found in AML12 cells (immortalized cell line from normal murine hepatocytes) PHB1 expression inversely correlated with cell proliferation, suggesting a tumor suppressive role in hepatocytes. (12) This, in addition to our recent observation that PHB1 expression falls in chronic cholestasis, prompted us to investigate whether it may play a role in HCC and in cholestasis-associated CCA development.
We focused on the interplay between PHB1, c-MYC, and MATa1 in HCC and CCA because PHB1 expression is lower in Mat1a KO mice (10) ; and we found that c-MYC also interacts with MATa1 and that they regulate each other in a reciprocal manner through the E-box in both HCC and CCA cells. (8) In addition, two other transcription factors, MAFG and c-MAF, interact with c-MYC and MATa1 and, like c-MYC, act as oncoproteins in CCA. (8) We found that PHB1 can directly interact with MATa1, MAFG, and MAX. MAX is a basic helix-loop-helixleucine zipper transcription factor that can heterodimerize with c-MYC, MNT, or MGA (the latter two are referred to as MAD proteins); and these heterodimers compete for binding to the E-box. (23) The c-MYC/MAX heterodimer typically activates the E-box, whereas MNT/MAX turns off the E-box. (24) We found that PHB1 and MATa1 are similar to MNT and MGA in their ability to heterodimerize with MAX in order to bind to the E-box and repress Ebox-driven promoter activity. While c-MYC, MAFG, and c-MAF have E-boxes in their promoter regions that act as enhancers, (8) E-boxes in the human MAT1A and PHB1 promoter regions act to repress their gene transcription. In addition, c-MYC, MAFG, and c-MAF activate the E-box, but MATa1 and PHB1 repress the E-box. This results in PHB1 and MAT1A positively regulating each other, whereas PHB1 and MAT1A exert reciprocal regulation against c-MYC/MAFG/c-MAF.
PHB1 is growth-suppressive in two HCC and two CCA cell lines. It is down-regulated in the majority of both human HCC and CCA at the mRNA level. Because PHB1's effect may be mediated through MAT1A, which we showed behaves as a tumor suppressor in HCC and CCA, (8) we used SAMe-D cells, which are derived from HCC of a Mat1a KO mouse, (16) to examine the effect of PHB1 on in vitro tumorigenicity. We found that increased PHB1 expression lowered the expression of c-MYC, MAFG, and c-MAF and inhibited anchorage-independent growth, which is consistent with its role as a tumor suppressor in hepatocytes. Because SAMe-D cells do not express MAT1A, the effect of PHB1 is not mediated by raising MAT1A expression in these cells.c-MYC expression is elevated or deregulated in up to 70% of human cancers by different mechanisms and is linked to an aggressive cancer phenotype, including liver cancer. (23) (24) (25) We showed a critical role for c-MYC induction in a mouse model of cholestasis-associated CCA. (9) Multiple mechanisms participate in the induction of c-MYC, including down-regulation of microRNA 34a and MAT1A expression during cholestasis. (8, 9) Our current work adds down-regulation of PHB1 expression as a feed-forward mechanism. The reciprocal regulation between PHB1 and c-MYC illustrates a complex crosstalk between these two proteins that participates in the progression of cholestatic liver injury and likely the development of liver cancers. We previously showed during chronic cholestasis by bile duct ligation or treatment with lithocholic acid that c-MYC lowered PHB1 expression by a mechanism that involves microRNAs 27a and 27b, which are c-MYC target genes that target PHB1. (6) Our current work shows that c-MYC also represses PHB1 transcriptional activity, which in turn facilitates sustained c-MYC induction. In hepatocytes and cholangiocytes the effect of PHB1 on c-MYC transcriptional activity involves direct repression by PHB1/MAX as well as an indirect mechanism as PHB1 positively regulates MAT1A expression, another repressor of c-MYC, but negatively regulates MAFG and c-MAF, two activators of c-MYC. (8) Indeed, liver-specific Phb1 KO mice have very low MAT1A but markedly induced c-MYC expression. These mice develop HCC and abnormal bile duct proliferations by 8 months of age. Because these mice have baseline liver injury, we further examined whether reduced PHB1 expression could sensitize the animal to develop cholestasis-associated CCA. We previously established the mouse CCA model using DEN and LMBDL as LMBDL alone did not result in CCA in wild-type mice and, even with the combination of DEN and LMBDL, CCA development required a long time (28 weeks). (9) Liver-specific Phb1 heterozygotes exhibit no overt phenotype, have normal liver histology and biochemistry, but are sensitized to develop abnormal bile duct proliferation and CCA, only 3.5 months after LMBDL alone. This strongly supports PHB1's role as a tumor suppressor in cholestasis-associated CCA. Consistently, PHB1 expression is reduced in the murine CCA model, and its expression inversely correlates with c-MYC expression and tumor growth. While our current work is focused on the interplay between PHB1 with MATa1 and c-MYC on the E-box, the increased sensitivity of Phb1 heterozygotes to cholestasis-induced CCA development is likely multifactorial. LMBDL reduced the expression of PHB1 and GSH synthetic enzymes, and these were accentuated in Phb1 heterozygotes. Reduced PHB1 expression can lower the expression of GSH synthetic enzymes as well as impair mitochondrial function, resulting in higher oxidative stress that can cause DNA damage. These mechanisms likely also participate in the cholestasis-induced CCA.
Although cholestasis raises the hepatic and serum levels of multiple bile acids, there is controversy as to whether these bile acids are important in the development of cholestatic liver injury as the toxic bile acids do not increase to high enough levels. (26) In patients with advanced primary biliary cirrhosis, elevated serum CA and CDCA (30-40 lM) have been reported (glycoconjugate represents 50%-55%, taurine conjugate 40%-45%). (27) Based on these reports, we examined the effects of 50-100 lM of GDCA, CA, and CDCA compared to lithocholic acid (as positive control) in H69 cells. CA and CDCA had no effects on PHB1 or c-MYC expression even at 100 lM after 16 hours. GDCA had an effect but only at 100 lM. Because this is unlikely to be relevant during bile duct ligation, we then explored the possibility that IL-6 may be involved in triggering the observed changes in gene expression during bile duct ligation. We chose IL-6 because its level is higher after bile duct ligation and in patients with HCC and CCA. (28) (29) (30) We found that IL-6 (10 ng/mL) treatment of H69 cells for only 4 hours significantly reduced MAT1A and PHB1 mRNA levels by 22% and 26%, respectively, and raised c-MYC, MAFG, and c-MAF by 40%-53%. These results suggest that bile acids are not likely to be responsible for causing the changes in these genes but, rather, proinflammatory cytokines such as IL-6. How this occurs and whether other cytokines are also involved will be a subject of future investigation.
Given the heterogeneity of HCC and CCA, it is no surprise that not all human specimens showed downregulation of PHB1. However, the majority of available paired samples (CCA and adjacent nontumorous tissue) from three different institutions showed lowering of PHB1 mRNA levels in CCA, with an average of 70% lowering in 14 out of 17 samples. This is also true for HCC, where 22 of 33 showed an average of 56% lowering of PHB1 mRNA levels. Our results are consistent with the publically available microarray data sets from the GEO database, where PHB1 mRNA levels appear to be lower in CCA compared to HCC. Future work will examine differences in the tumors that may explain why some express lower PBH1 but others do not.
In summary, our current work shows an important role for PHB1 in both HCC and CCA, where it acts as a transcription factor that heterodimerizes with MAX and represses the E-box. In so doing it negatively regulates three transcription factors-c-MYC, MAFG, and c-MAF-which we showed exhibit oncogenic activity in HCC and CCA, whereas it positively regulates MAT1A, a tumor suppressor in both cancers. Although the current work extends the complex interplay between MATa1, c-MYC, MAFG, and c-MAF we showed recently, (8) the findings are important for PHB1 biology and establish PHB1 as a tumor suppressor in liver cancer. In addition, we show that both MATa1 and PHB1 behave like MAD proteins in forming heterodimers with MAX to repress the E-box-driven promoter activity. Finally, the finding that reduced PHB1 expression predisposes the animal to cholestasis-associated CCA has important clinical implications as we have shown that PHB1 expression is reduced in patients with primary biliary cirrhosis and Alagille syndrome. (7) 
